NRP1 and neoplasm: These observations point to the broader conclusion that in VEGF-driven tumor cells where Nrp1 is highly expressed, pharmacological targeting of the b1 domain by small molecules, like EG00229, may be critical to curb tumor progression and limit CSC maintenance.